# A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects

> **NCT03125213** · PHASE2 · WITHDRAWN · sponsor: **Alios Biopharma Inc.**

## Conditions studied

- Hepatitis B, Chronic

## Interventions

- **DRUG:** AL-3778
- **DRUG:** Peginterferon Alfa-2A
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03125213
- **Lead sponsor:** Alios Biopharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2017-09-12
- **Primary completion:** 2019-02-15
- **Final completion:** 2019-02-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor decision.
- **Last updated:** 2017-10-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03125213

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03125213, "A Study Evaluating AL-3778 in Combination With Peginterferon Alpha-2a in Chronic Hepatitis B Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03125213. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*